Johnson & Johnson has become the latest Big Pharma to turn to PeptiDream for help discovering and optimizing peptide therapeutics.

With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical…

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

Heptares Therapeutics has struck a pain drug R&D pact with Daiichi Sankyo.

Galapagos has turned to Pharnext to identify low-doses of approved drugs that boost the efficacy of its pipeline prospects.

Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell.